JP2024537772A5 - - Google Patents
Info
- Publication number
- JP2024537772A5 JP2024537772A5 JP2024519268A JP2024519268A JP2024537772A5 JP 2024537772 A5 JP2024537772 A5 JP 2024537772A5 JP 2024519268 A JP2024519268 A JP 2024519268A JP 2024519268 A JP2024519268 A JP 2024519268A JP 2024537772 A5 JP2024537772 A5 JP 2024537772A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- binding site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163250092P | 2021-09-29 | 2021-09-29 | |
| US63/250,092 | 2021-09-29 | ||
| PCT/US2022/077068 WO2023056243A1 (en) | 2021-09-29 | 2022-09-27 | Antibodies targeting baff-r and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537772A JP2024537772A (ja) | 2024-10-16 |
| JP2024537772A5 true JP2024537772A5 (enExample) | 2025-10-07 |
Family
ID=85780903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519268A Pending JP2024537772A (ja) | 2021-09-29 | 2022-09-27 | Ｂａｆｆ－ｒを標的化する抗体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240228645A1 (enExample) |
| EP (1) | EP4408891A4 (enExample) |
| JP (1) | JP2024537772A (enExample) |
| KR (1) | KR20240069787A (enExample) |
| CN (1) | CN118317975A (enExample) |
| AR (1) | AR127163A1 (enExample) |
| AU (1) | AU2022354054A1 (enExample) |
| CA (1) | CA3233246A1 (enExample) |
| IL (1) | IL311600A (enExample) |
| MX (1) | MX2024003913A (enExample) |
| TW (1) | TW202330604A (enExample) |
| WO (1) | WO2023056243A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| EP4786496A1 (en) * | 2023-09-28 | 2026-08-05 | Nanjing Iaso Biotechnology Co., Ltd. | Fully-human antibody and car-t cell targeting baff-r and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0518994A2 (pt) * | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| JP5425180B2 (ja) * | 2008-03-27 | 2014-02-26 | ザイモジェネティクス， インコーポレイテッド | ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法 |
| AU2009272771B2 (en) * | 2008-07-17 | 2012-09-20 | Novartis Ag | Compositions and methods of use for therapeutic antibodies |
| CA2748161A1 (en) * | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| US11136405B2 (en) * | 2016-06-06 | 2021-10-05 | Board Of Regents, The Unviersity Of Texas System | BAFF-R antibodies and uses thereof |
| WO2021163989A1 (en) * | 2020-02-21 | 2021-08-26 | Yinnuolai Biotech Ltd. | Anti-baff receptor antibodies and uses thereof |
-
2022
- 2022-09-27 JP JP2024519268A patent/JP2024537772A/ja active Pending
- 2022-09-27 KR KR1020247013643A patent/KR20240069787A/ko active Pending
- 2022-09-27 AR ARP220102598A patent/AR127163A1/es unknown
- 2022-09-27 IL IL311600A patent/IL311600A/en unknown
- 2022-09-27 CN CN202280064772.4A patent/CN118317975A/zh active Pending
- 2022-09-27 AU AU2022354054A patent/AU2022354054A1/en active Pending
- 2022-09-27 CA CA3233246A patent/CA3233246A1/en active Pending
- 2022-09-27 WO PCT/US2022/077068 patent/WO2023056243A1/en not_active Ceased
- 2022-09-27 TW TW111136545A patent/TW202330604A/zh unknown
- 2022-09-27 MX MX2024003913A patent/MX2024003913A/es unknown
- 2022-09-27 EP EP22877491.5A patent/EP4408891A4/en not_active Withdrawn
-
2024
- 2024-03-28 US US18/620,375 patent/US20240228645A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11919958B2 (en) | Anti-CD28 compositions | |
| JP2022551757A5 (enExample) | ||
| IL311600A (en) | Antibodies targeting BAFF-R and their use | |
| JP7854121B2 (ja) | 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法 | |
| IL317912A (en) | A combined chimeric antigen receptor targeting CD19 and CD20 and its applications | |
| JP2023524997A5 (enExample) | ||
| JP2021526844A5 (enExample) | ||
| CA3091764A1 (en) | Antibody variable domains targeting cd33, and use thereof | |
| CA3020864A1 (en) | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| JP2023546766A5 (enExample) | ||
| WO2019101695A1 (en) | Multispecific antigen binding proteins | |
| JP2024537779A5 (enExample) | ||
| JP2023525778A5 (enExample) | ||
| JP2024534847A5 (enExample) | ||
| US20250043001A1 (en) | Anti-cd28 compositions | |
| JP2024541476A5 (enExample) | ||
| TW202221015A (zh) | 單一及雙靶定配體誘導之t細胞銜接體組合物 | |
| US20250084186A1 (en) | Anti-cd28 x anti-enpp3 antibodies | |
| TW202525853A (zh) | 抗ｃｄ２０ｘ抗ｃｄ２８組合療法 | |
| JP2021524451A (ja) | 最適化済みｇｐ４１結合分子及びその使用 | |
| EP4469478A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen | |
| JP2023517889A5 (enExample) | ||
| JP2025505933A5 (enExample) | ||
| US20260070982A1 (en) | Antigen binding molecules to cd3 and cd19 | |
| HK40073541A (en) | Miniature guidance and navigation control (minignc) antibody-like proteins and methods of making and using thereof |